Safety and Efficacy of Mitapivat in Pyruvate Kinase DeficiencyRachael F. Grace, Bertil Glader, Christian Rosé et al.|New England Journal of Medicine|2019Cited by 162
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 studyKevin H.M. Kuo, Elliott Vichinsky, D. Mark Layton et al.|The Lancet|2022Cited by 87
The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study designRachael F. Grace, Paola Bianchi, Hitoshi Kanno et al.|BMJ Open|2023Cited by 8
Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-ThalassemiaKevin H.M. Kuo, Elliott Vichinsky, D. Mark Layton et al.|Blood|2021Cited by 7
Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK StudyRachael F. Grace, Bertil Glader, Christian Rosé et al.|Blood|2016Cited by 6